BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X. Host b7x promotes pulmonary metastasis of breast cancer. J Immunol 2013;190:3806-14. [PMID: 23455497 DOI: 10.4049/jimmunol.1202439] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Podojil JR, Glaser AP, Baker D, Courtois ET, Fantini D, Yu Y, Eaton V, Sivajothi S, Chiang M, Das A, McLaughlin KA, Robson P, Miller SD, Meeks JJ. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. Oncoimmunology 2020;9:1744897. [PMID: 32363111 DOI: 10.1080/2162402X.2020.1744897] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
2 Qian Y, Sang Y, Wang FX, Hong B, Wang Q, Zhou X, Weng T, Wu Z, Zheng M, Zhang H, Yao H. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases. Oncotarget 2016;7:72242-9. [PMID: 27750217 DOI: 10.18632/oncotarget.12665] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
3 Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A 2013;110:9879-84. [PMID: 23716685 DOI: 10.1073/pnas.1303524110] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 9.1] [Reference Citation Analysis]
4 Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep 2014;9:1089-98. [PMID: 25437562 DOI: 10.1016/j.celrep.2014.09.053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
5 Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014;33:1025-41. [PMID: 25359584 DOI: 10.1007/s10555-014-9529-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
6 Rees JS, Cheung LCC, Hamaia SW, Davies G, Sandercock A, Lilley KS, Tigue N, Jackson AP. Identification of the cis‑molecular neighbours of the immune checkpoint protein B7‑H4 in the breast cancer cell‑line SK‑BR‑3 by proteomic proximity labelling. Int J Oncol 2020;57:87-99. [PMID: 32319587 DOI: 10.3892/ijo.2020.5037] [Reference Citation Analysis]
7 Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, Firestein R, Li D, Schutten M, Stagg NJ, Ogasawara A, Koppada N, Roth L, Williams SP, Lee BC, Chalouni C, Peng I, DeVoss J, Tremayne J, Polakis P, Polson AG. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm 2015;12:1717-29. [PMID: 25853436 DOI: 10.1021/mp5007745] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
8 Podojil JR, Chiang MY, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, Chen L, Vignali DAA, Miller SD. B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex. J Immunol 2018;201:897-907. [PMID: 29898965 DOI: 10.4049/jimmunol.1700811] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
9 John P, Wei Y, Liu W, Du M, Guan F, Zang X. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial. Trends Pharmacol Sci 2019;40:883-96. [PMID: 31677920 DOI: 10.1016/j.tips.2019.09.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
10 Chen C, Qu QX, Xie F, Zhu WD, Zhu YH, Huang JA. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists. BMC Cancer 2017;17:652. [PMID: 28923053 DOI: 10.1186/s12885-017-3615-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Pawar RD, Goilav B, Xia Y, Herlitz L, Doerner J, Chalmers S, Ghosh K, Zang X, Putterman C. B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. Clin Exp Immunol 2015;179:329-43. [PMID: 25205493 DOI: 10.1111/cei.12452] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
12 Wang M, Liu Y, Cheng Y, Wei Y, Wei X. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochim Biophys Acta Rev Cancer. 2019;1871:199-224. [PMID: 30605718 DOI: 10.1016/j.bbcan.2018.12.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
13 Johnson AA, Shokhirev MN. Pan-Tissue Aging Clock Genes That Have Intimate Connections with the Immune System and Age-Related Disease. Rejuvenation Res 2021;24:377-89. [PMID: 34486398 DOI: 10.1089/rej.2021.0012] [Reference Citation Analysis]
14 Liu J, Pang Z, Wang G, Guan X, Fang K, Wang Z, Wang F. Advanced Role of Neutrophils in Common Respiratory Diseases. J Immunol Res 2017;2017:6710278. [PMID: 28589151 DOI: 10.1155/2017/6710278] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
15 Ding S, Lv X, Liu Z, Zhan S, Xu Y, Zhang X, Liu C, Cao L. Overexpression of B7-H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer. Int Immunopharmacol 2021;90:107144. [PMID: 33187907 DOI: 10.1016/j.intimp.2020.107144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev 2017;276:52-65. [DOI: 10.1111/imr.12524] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 14.2] [Reference Citation Analysis]
17 Smith JB, Stashwick C, Powell DJ. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol 2014;134:181-9. [PMID: 24657487 DOI: 10.1016/j.ygyno.2014.03.553] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
18 Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clin Cancer Res 2015;21:2359-66. [PMID: 25549724 DOI: 10.1158/1078-0432.CCR-14-1495] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
19 Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 2016;44:955-72. [PMID: 27192563 DOI: 10.1016/j.immuni.2016.05.002] [Cited by in Crossref: 266] [Cited by in F6Publishing: 256] [Article Influence: 53.2] [Reference Citation Analysis]
20 Zeng S, Song H, Chen Y, Xie W, Zhang L. B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors. Mol Biol 2016;50:887-94. [DOI: 10.1134/s0026893316060248] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Wang L, Heng X, Lu Y, Cai Z, Yi Q, Che F. Could B7-H4 serve as a target to activate anti-cancer immunity? International Immunopharmacology 2016;38:97-103. [DOI: 10.1016/j.intimp.2016.05.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
22 Liu W, Almo SC, Zang X. Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go? Immunol Invest 2016;45:813-31. [PMID: 27419268 DOI: 10.1080/08820139.2016.1186690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
23 Dastmalchi N, Safaralizadeh R, Baghbanzadeh A, Hajiasgharzadeh K, Roshani Asl E, Amini M, Baradaran B. Molecular mechanisms of breast cancer chemoresistance by immune checkpoints. Life Sci 2020;263:118604. [PMID: 33096117 DOI: 10.1016/j.lfs.2020.118604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kaur G, Janakiram M. B7x-from bench to bedside. ESMO Open 2019;4:e000554. [PMID: 31555486 DOI: 10.1136/esmoopen-2019-000554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13:143-158. [PMID: 26598942 DOI: 10.1038/nrclinonc.2015.209] [Cited by in Crossref: 463] [Cited by in F6Publishing: 453] [Article Influence: 66.1] [Reference Citation Analysis]
26 Deng WW, Wu L, Sun ZJ. Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma. Oral Dis 2018;24:120-3. [PMID: 29480599 DOI: 10.1111/odi.12746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Cai X, Ge N, Rong R, Lu Y, Zhang J, Xu J. High expression of BTLA and B7-H4 on the surface of myeloid dendritic cells has a negative regulatory effect on their anti-tuberculosis immunity activity in pleural tuberculosis patients. Tuberculosis (Edinb) 2019;119:101877. [PMID: 31677529 DOI: 10.1016/j.tube.2019.101877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol 2018;2:4. [PMID: 29872722 DOI: 10.1038/s41698-018-0047-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 18.8] [Reference Citation Analysis]
29 Jeon H, Ohaegbulam KC, Abadi YM, Zang X. B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology 2013;2:e24744. [PMID: 24073367 DOI: 10.4161/onci.24744] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
30 Wang L, Yang C, Liu XB, Wang L, Kang FB. B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. Cancer Cell Int 2018;18:100. [PMID: 30008617 DOI: 10.1186/s12935-018-0597-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
31 Tsiaousidou A, Tsaroucha AK, Lambropoulou M, Pitiakoudis M, Polychronidis A, Chatzitheoklitos E, Romanidis K, Simopoulos C. Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma. Clin Exp Med 2016;16:351-6. [DOI: 10.1007/s10238-015-0352-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
32 Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev 2017;276:26-39. [PMID: 28258693 DOI: 10.1111/imr.12521] [Cited by in Crossref: 86] [Cited by in F6Publishing: 94] [Article Influence: 17.2] [Reference Citation Analysis]
33 Leung J, St-Onge P, Stagg J, Suh WK. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model. Cancer Immunol Immunother 2017;66:491-502. [PMID: 28074226 DOI: 10.1007/s00262-016-1950-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
34 Podojil JR, Ifergan I, Chiang MY, Meeks JJ, Miller SD. Methodology for in vitro Assessment of Human T Cell Activation and Blockade. Bio Protoc 2020;10:e3644. [PMID: 33659314 DOI: 10.21769/BioProtoc.3644] [Reference Citation Analysis]
35 Leung J, Suh WK. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw 2014;14:265-76. [PMID: 25550693 DOI: 10.4110/in.2014.14.6.265] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
36 Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F, Xu Y, Zhao Y, Wu Z, Xu Y. Mechanism of immune evasion in breast cancer. Onco Targets Ther 2017;10:1561-73. [PMID: 28352189 DOI: 10.2147/OTT.S126424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
37 Gorczynski RM, Chen Z, Erin N, Khatri I, Podnos A. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One 2014;9:e113597. [PMID: 25409195 DOI: 10.1371/journal.pone.0113597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
38 Fukuda T, Kamai T, Masuda A, Nukui A, Abe H, Arai K, Yoshida K. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Med 2016;5:1810-20. [PMID: 27292320 DOI: 10.1002/cam4.754] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
39 Ohaegbulam KC, Liu W, Jeon H, Almo SC, Zang X. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells. Oncotarget 2017;8:82740-53. [PMID: 29137299 DOI: 10.18632/oncotarget.21098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
40 Che F, Heng X, Zhang H, Su Q, Zhang B, Chen Y, Zhang Z, Du Y, Wang L. Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. Cancer Immunol Immunother. 2017;66:717-729. [PMID: 28246881 DOI: 10.1007/s00262-017-1961-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
41 Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. Mol Ther 2016;24:1987-99. [PMID: 27439899 DOI: 10.1038/mt.2016.149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]